½ÃÀ庸°í¼­
»óǰÄÚµå
1602726

¼¼°èÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå : ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Anatomic Pathology Market by Services (Cytopathology, Histopathology), Product (Consumables, Instruments), Application, End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 194 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÇØºÎ º´¸®ÇÐ(Anatomic Pathology) ½ÃÀåÀº 2023³â 343¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 369¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤ µÇ¸ç, CAGR 7.56%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 572¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÇØºÎ º´¸®ÇÐÀº Àå±â, Á¶Á÷ ¹× ¼¼Æ÷ °Ë»ç¸¦ ±â¹ÝÀ¸·Î Áúº´À» Áø´ÜÇÏ´Â ÀÇÇÐÀÇ ÇÑ ºÐ¾ßÀÔ´Ï´Ù. ÇØºÎÇÐÀû º´¸®ÇÐÀÇ ¹üÀ§´Â ¼ö¼ú º´¸®ÇÐ, ¼¼Æ÷º´¸®ÇÐ ¹× ¹ýÀÇÇÐ º´¸®Çаú °ü·ÃµÈ Ä¡·á °áÁ¤¿¡ µµ¿òÀÌ µÇ´Â ÀλçÀÌÆ®¸¦ Á¦°øÇÏ´Â »ý¹°ÇÐÀû Ç¥º»¿¡ ´ëÇÑ Æ÷°ýÀûÀÎ ¿¬±¸¸¦ Æ÷ÇÔÇÕ´Ï´Ù. ÇØºÎÇÐÀû º´¸®ÇÐÀº ¾ÏÀ» Æ÷ÇÔÇÑ ¼ö¸¹Àº ÁúȯÀ» Áø´ÜÇÏ´Â µ¥ ±Ùº»ÀûÀÎ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ ÀÏ»óÀûÀÎ ÀÓ»ó Àû¿ë°ú Àü¹® Áø´Ü ÀýÂ÷ ¸ðµÎ¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÇØºÎÇÐÀû º´¸®ÇÐÀÇ Àû¿ëÀº ÀÓ»ó ȯ°æ, ¿¬±¸ ±â°ü ¹× Çмú ´Üü¿¡ °ÉÃÄ ÀÌ·ç¾îÁö¸ç, ÀϹÝÀûÀ¸·Î º´¿ø, Áø´Ü ½ÇÇè½Ç ¹× Àü¹® Ŭ¸®´Ð¿¡¼­ ÃÖÁ¾ ¿ëµµ·Î »ç¿ëµË´Ï´Ù. ½ÃÀå ÀλçÀÌÆ®¿¡ µû¸£¸é ¼ºÀåÀº ÁÖ·Î Áø´Ü Á¤È®¼º°ú È¿À²¼ºÀ» Çâ»ó½ÃŰ´Â µðÁöÅÐ º´¸®ÇÐ ¹× AI ÅëÇÕ°ú °°Àº ±â¼ú ¹ßÀü¿¡ ÀÇÇØ ÁÖµµµÈ´Ù´Â »ç½ÇÀÌ ¹àÇôÁ³½À´Ï´Ù. ¸¸¼º Áúȯ, ¾Ï À¯º´·ü ¹× °í·ÉÈ­´Â ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ãŵ´Ï´Ù. ¹Ý´ë·Î, ÷´Ü ±â¼ú°ú °ü·ÃµÈ ³ôÀº ºñ¿ë°ú ½ÃÀå È®ÀåÀ» ´ÊÃâ ¼ö ÀÖ´Â ¼÷·ÃµÈ º´¸®ÇÐÀÚÀÇ ºÎÁ· µîÀÌ ÇѰèÀÔ´Ï´Ù. ¶ÇÇÑ ±ÔÁ¦ À庮Àº ½Å¼ÓÇÑ Çõ½Å ±¸Çö¿¡ Àå¾Ö¹°ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. °æÀï ¿ìÀ§¸¦ Á¦°øÇÏ°í ½ÃÀå Â÷º°È­¸¦ ÃËÁøÇÒ ¼ö ÀÖ´Â AI ±â¹Ý Áø´Ü µµ±¸¿Í °³ÀÎÈ­µÈ ÀÇÇÐ Á¢±Ù ¹æ½ÄÀÇ °³¹ß¿¡ ±âȸ°¡ ÀÖ½À´Ï´Ù. Çаè¿Í ¾÷°è °ü°èÀÚ °£ÀÇ Çù·ÂÀû ¿¬±¸ ³ë·ÂÀº ÀÌ·¯ÇÑ ¹ßÀüÀ» °¡¼ÓÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀáÀçÀû ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇÑ ÁÖ¿ä ±ÇÀå »çÇ×À¸·Î´Â ÷´Ü Áø´Ü µµ±¸¸¦ À§ÇÑ R&D¿¡ ÅõÀÚÇÏ°í ¿ø°Ý º´¸®ÇÐ ¹× ¿ø°Ý Áø´ÜÀ» Áö¿øÇϱâ À§ÇÑ µðÁöÅÐ ÀÎÇÁ¶ó¸¦ °­È­ÇÏ´Â °ÍÀÌ ÀÖ½À´Ï´Ù. °¡Àå ÁÁÀº Çõ½Å ºÐ¾ß´Â º´¸® ¿öÅ©Ç÷ο쿡 ¸Ó½Å ·¯´× ¾Ë°í¸®ÁòÀ» ÅëÇÕÇϰí ÃÖ¼Ò Ä§½ÀÀû Áø´Ü ±â¼úÀ» °³¹ßÇÏ´Â °ÍÀÔ´Ï´Ù. ÇØºÎÇÐÀû º´¸®ÇÐ ½ÃÀåÀº ¿ªµ¿ÀûÀÌ°í °æÀïÀÌ Ä¡¿­Çϸç, ºü¸¥ ±â¼ú äÅðú Áø´Ü °üÇàÀÇ Á¤È®¼º°ú È¿À²¼º¿¡ ´ëÇÑ °­Á¶°¡ Ư¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Æ¯¼º»ó »õ·Î¿î Æ®·»µå¸¦ Ȱ¿ëÇÏ°í ¾÷°èÀÇ ³»ÀçµÈ °úÁ¦¸¦ ±Øº¹Çϱâ À§Çؼ­´Â Áö¼ÓÀûÀÎ ¿¬±¸, ÅõÀÚ ¹× Àü·«Àû ÆÄÆ®³Ê½ÊÀÌ ÇÊ¿äÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ¿¬µµ(2023³â) 343¾ï 8,000¸¸ ´Þ·¯
ÃßÁ¤¿¬µµ(2024³â) 369¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø¿¬µµ(2030³â) 572¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 7.56%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ÇØºÎ º´¸®ÇÐ ½ÃÀåÀÇ ÁÖ¿ä ÀλçÀÌÆ® °ø°³

ÇØºÎ º´¸®ÇÐ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­ÇÏ´Â ½ÃÀå ¿ªÇÐÀ» ÀÌÇØÇÏ¸é ºñÁî´Ï½º Á¶Á÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç °áÁ¤À» °³¼±Çϸç, »õ·Î¿î ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ºñÁî´Ï½º Á¶Á÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡¼­ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÏ´Â µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å Æ®·»µå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ´õ ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¹ÙÀÌ¿À¸¶Ä¿¿¡ ±Ù°ÅÇÑ º´¸®ÇÐÀû °Ë»ç¡¤Ã³Ä¡¿¡ ´ëÇÑ ½Å·Ú °íÁ¶
    • ¾Ï ¹× ±âŸ ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡
    • ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÁÖ¸ñ °íÁ¶
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÀÌ¿ë °¡´ÉÇÑ ±Ô°ÝÀÌ ÇÑÁ¤µÇ¾î ÀÖ¾î, ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • ±Û·Î½º À̹Ì¡, ¿°»ö ½Ã½ºÅÛ, µðÁöÅÐ ¸¶ÀÌÅ©·Î½ºÄÚÇÁ µî °í±Þ º´¸® °Ë»ç ±â±âÀÇ »ç¿ë Áõ°¡
    • È¿°úÀûÀÎ Æ÷Æ®Æú¸®¿À µµÀÔÀ» À§ÇÑ ±â¾÷ °£ Àü·«Àû Á¦ÈÞ¿Í ÇÕÀÇ
  • ½ÃÀå °úÁ¦
    • ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·

Porter's Five Forces : ÇØºÎ º´¸®ÇÐ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ºñÁî´Ï½º Á¶Á÷¿¡ °æÀïÀû À§Ä¡¸¦ Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ý·ÐÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ÈûÀÇ ¿ªÇÐ °ü°è¸¦ Æò°¡ÇÏ°í »õ·Î¿î º¥Ã³ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» ÇØ°áÇϸç ÀáÀçÀûÀÎ ¹®Á¦¸¦ ¹æÁöÇÏ¿© º¸´Ù ź·ÂÀûÀÎ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÇØºÎ º´¸®ÇÐ ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÇØºÎ º´¸®ÇÐ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡, °æÁ¦, »çȸ, ±â¼ú, ¹ý·ü ¹× ȯ°æ ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ¿© ¼±Á¦ÀûÀÌ°í ¹Ì·¡ ÁöÇâÀûÀÎ ÀÇ»ç °áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ÇØºÎ º´¸®ÇÐ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

ÇØºÎ º´¸®ÇÐ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü µîÀÇ ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© ÀÚ»çÀÇ °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀå ÁýÁßµµ, ¼¼ºÐÈ­, ÅëÇÕ Ãß¼¼¸¦ °­Á¶ÇÏ¿© º¥´õ°¡ °æÀïÀÌ Ä¡¿­ÇØÁö´Â ȯ°æ¿¡¼­ ÀÔÁö¸¦ °­È­ÇÏ´Â Àü·«Àû °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ÇØºÎ º´¸®ÇÐ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÇØºÎ º´¸®ÇÐ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. 4°³ÀÇ »çºÐ¸éÀº °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© »ç¿ëÀÚ°¡ Àü·«Àû ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

Àü·« ºÐ¼® ¹× Á¦¾È : ÇØºÎ º´¸®ÇÐ ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ °æ·Î ±×¸®±â

ÇØºÎ º´¸®ÇÐ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº Àü ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö °­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¹ÙÀÌ¿À¸¶Ä¿¿¡ ±âÃÊÇÑ º´¸®°Ë»ç¿Í ÀýÂ÷¿¡ ´ëÇÑ ÀÇÁ¸µµ Áõ°¡
      • ¾ÏÀ̳ª ±âŸ ¸¸¼ºÁúȯÀÇ ÀÌȯÀ² Áõ°¡
      • ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÁÖ·ÂÀ» °¡¼Ó
    • ¾ïÁ¦¿äÀÎ
      • Á¤ÀÇµÈ Ç¥ÁØÀÇ ÀÔ¼ö°¡ ÇÑÁ¤µÇ¾î ÀÖ¾î ³ôÀº ºñ¿ë
    • ±âȸ
      • ±Û·Î½º À̹Ì¡, ¿°»ö ½Ã½ºÅÛ, µðÁöÅÐ Çö¹Ì°æ µî °í±Þ º´¸®ÇÐ ±â±âÀÇ »ç¿ë Áõ°¡
      • È¿°úÀûÀÎ Æ÷Æ®Æú¸®¿À ¼Ò°³¸¦ À§ÇÑ ±â¾÷ °£ Àü·«Àû ÆÄÆ®³Ê½Ê°ú ÇÕÀÇ
    • °úÁ¦
      • ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
    • ¹ýÀû
    • ȯ°æÀû

Á¦6Àå ÇØºÎ º´¸®ÇÐ ½ÃÀå : ¼­ºñ½ºº°

  • ¼¼Æ÷º´¸®ÇÐ
  • Á¶Á÷º´¸®ÇÐ

Á¦7Àå ÇØºÎ º´¸®ÇÐ ½ÃÀå : Á¦Ç°º°

  • ¼Ò¸ðǰ
    • Ç×ü
    • ŰƮ ¹× ½Ã¾à
    • ÇÁ·Îºê
  • ±â±â
    • ¼¿ ÇÁ·Î¼¼¼­
    • Ä¿¹ö ½½¸®ÆÛ
    • ÀÓº£µðµå ½Ã½ºÅÛ
    • ¸¶ÀÌÅ©·ÎÅè
    • ½½¶óÀÌµå ¿°»ö ½Ã½ºÅÛ
    • Á¶Á÷ ó¸® ½Ã½ºÅÛ

Á¦8Àå ÇØºÎ º´¸®ÇÐ ½ÃÀå : ¿ëµµº°

  • Áúº´ÀÇ Áø´Ü
  • ÀÇÇÐ Á¶»ç

Á¦9Àå ÇØºÎ º´¸®ÇÐ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ÀÓ»ó ½ÇÇè½Ç
  • º´¿ø °Ë»ç½Ç

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾Æ ÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÇØºÎ º´¸®ÇÐ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼® ¹× Á¦¾È

±â¾÷ ¸ñ·Ï

  • Agilent Technologies, Inc
  • Amos Scientific Pty Ltd
  • Bio SB
  • BioGenex Laboratories
  • Cardinal Health, Inc.
  • Diapath SpA
  • Enzo Biochem, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Histo-Line Laboratories
  • Milestone Medical
  • NeoGenomics Laboratories, Inc.
  • PHC Holdings Corporation
  • RareCyte, Inc.
  • Sakura Finetek USA, Inc.
  • VolitionRx Limited
LYJ

The Anatomic Pathology Market was valued at USD 34.38 billion in 2023, expected to reach USD 36.95 billion in 2024, and is projected to grow at a CAGR of 7.56%, to USD 57.27 billion by 2030.

Anatomic pathology is a branch of medicine concerned with the diagnosis of disease based on the examination of organs, tissues, and cells. The scope of anatomic pathology encompasses the comprehensive study of biological specimens to provide insights that aid in treatment decisions, which involve surgical pathology, cytopathology, and forensic pathology. Given its fundamental role in diagnosing a plethora of conditions including cancers, anatomic pathology is crucial for both routine clinical applications and specialized diagnostic procedures. The application of anatomic pathology spans clinical settings, research institutions, and academic entities, with end-uses typically in hospitals, diagnostic labs, and specialty clinics. Market insight reveals that growth is predominantly driven by technological advancements, such as digital pathology and AI integration, which enhance diagnostic accuracy and efficiency. The rise in chronic diseases, cancer prevalence, and the aging population further fuel demand. Conversely, limitations include high costs associated with advanced technologies and a shortage of skilled pathologists, which can slow market expansion. Additionally, regulatory barriers present obstacles to rapid innovation implementation. Opportunities reside in the development of AI-driven diagnostic tools and personalized medicine approaches, which can offer competitive advantages and foster market differentiation. Collaborative research efforts between academic institutions and industry players could accelerate these advancements. Key recommendations for tapping into potential opportunities include investing in R&D for advanced diagnostic tools and enhancing digital infrastructure to support telepathology and remote diagnostics. Best areas for innovation include the integration of machine learning algorithms in pathology workflows and the development of minimally invasive diagnostic techniques. The anatomic pathology market is dynamic and competitive, characterized by rapid technological adoption and a strong emphasis on accuracy and efficiency in diagnostic practices. This nature necessitates ongoing research, investment, and strategic partnerships to capitalize on emerging trends and overcome the inherent challenges within the industry.

KEY MARKET STATISTICS
Base Year [2023] USD 34.38 billion
Estimated Year [2024] USD 36.95 billion
Forecast Year [2030] USD 57.27 billion
CAGR (%) 7.56%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anatomic Pathology Market

The Anatomic Pathology Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising reliance on biomarkers-based pathology tests and procedures
    • Increasing prevalence of cancer and other chronic diseases
    • Accelerating focus towards personalized medicines
  • Market Restraints
    • Limited availability of defined standards and high cost
  • Market Opportunities
    • Growing use of advanced pathology equipment such as gross imaging, staining systems, and digital microscopes
    • Strategic partnership and agreement among companies for the introduction of an effective portfolio
  • Market Challenges
    • Dearth of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Anatomic Pathology Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anatomic Pathology Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anatomic Pathology Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anatomic Pathology Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anatomic Pathology Market

A detailed market share analysis in the Anatomic Pathology Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anatomic Pathology Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anatomic Pathology Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anatomic Pathology Market

A strategic analysis of the Anatomic Pathology Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anatomic Pathology Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc, Amos Scientific Pty Ltd, Bio SB, BioGenex Laboratories, Cardinal Health, Inc., Diapath S.p.A., Enzo Biochem, Inc., F. Hoffmann-La Roche Ltd., Histo-Line Laboratories, Milestone Medical, NeoGenomics Laboratories, Inc., PHC Holdings Corporation, RareCyte, Inc., Sakura Finetek USA, Inc., and VolitionRx Limited.

Market Segmentation & Coverage

This research report categorizes the Anatomic Pathology Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Services, market is studied across Cytopathology and Histopathology.
  • Based on Product, market is studied across Consumables and Instruments. The Consumables is further studied across Antibodies, Kits & Reagents, and Probes. The Instruments is further studied across Cell Processors, Coverslippers, Embedding Systems, Microtomes, Slide Staining Systems, and Tissue Processing Systems.
  • Based on Application, market is studied across Disease Diagnostics and Medical Research.
  • Based on End User, market is studied across Clinical Laboratories and Hospital Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising reliance on biomarkers-based pathology tests and procedures
      • 5.1.1.2. Increasing prevalence of cancer and other chronic diseases
      • 5.1.1.3. Accelerating focus towards personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability of defined standards and high cost
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing use of advanced pathology equipment such as gross imaging, staining systems, and digital microscopes
      • 5.1.3.2. Strategic partnership and agreement among companies for the introduction of an effective portfolio
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of skilled professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anatomic Pathology Market, by Services

  • 6.1. Introduction
  • 6.2. Cytopathology
  • 6.3. Histopathology

7. Anatomic Pathology Market, by Product

  • 7.1. Introduction
  • 7.2. Consumables
    • 7.2.1. Antibodies
    • 7.2.2. Kits & Reagents
    • 7.2.3. Probes
  • 7.3. Instruments
    • 7.3.1. Cell Processors
    • 7.3.2. Coverslippers
    • 7.3.3. Embedding Systems
    • 7.3.4. Microtomes
    • 7.3.5. Slide Staining Systems
    • 7.3.6. Tissue Processing Systems

8. Anatomic Pathology Market, by Application

  • 8.1. Introduction
  • 8.2. Disease Diagnostics
  • 8.3. Medical Research

9. Anatomic Pathology Market, by End User

  • 9.1. Introduction
  • 9.2. Clinical Laboratories
  • 9.3. Hospital Laboratories

10. Americas Anatomic Pathology Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Anatomic Pathology Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Anatomic Pathology Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agilent Technologies, Inc
  • 2. Amos Scientific Pty Ltd
  • 3. Bio SB
  • 4. BioGenex Laboratories
  • 5. Cardinal Health, Inc.
  • 6. Diapath S.p.A.
  • 7. Enzo Biochem, Inc.
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Histo-Line Laboratories
  • 10. Milestone Medical
  • 11. NeoGenomics Laboratories, Inc.
  • 12. PHC Holdings Corporation
  • 13. RareCyte, Inc.
  • 14. Sakura Finetek USA, Inc.
  • 15. VolitionRx Limited
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦